
    
      A double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled,
      Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to
      Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to
      Placebo, using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers
    
  